Navigation Links
Louisiana Tech researchers feature drug reformulation in prestigious journal
Date:7/11/2008

Dr. Yuri Lvov, a professor of chemistry and T. Pipes endowed chair in micro and nanosystems at Louisiana Tech University, and Anshul Agarwal, a Louisiana Tech doctoral candidate in biomedical engineering feature their cancer drug reformulation work in the most recent issue of Pharma Focus Asia, one of the largest and most respected pharmaceutical science journals in the world.

"This is the largest Asian pharmacological journal and is turned to by millions of people working in the medical industry," says Lvov.

Lvov and Agarwal also share the cover of Pharma Focus Asia with some of the world's leading nanotechnology experts including Dr. George Whitesides of Harvard University, one of the top nanotechnology researchers in the U.S, who was also featured in this issue.

"The recognition that Dr. Lvov has received through this cover story confirms the world-wide leadership position that his research, his colleagues, and Louisiana Tech University holds," says Dr. Stan Napper, dean of Louisiana Tech's College of Engineering and Science.

Working from Louisiana Tech's Institute for Micromanufacturing, Lvov and Agarwal collaborated with pharmaceutical researchers from Northeastern University in Boston on an article titled "Sonication-Assisted Nanoencapsulation." The article looks at nanoencapsulation of low soluble cancer drugs and presents an innovative approach for adjusting drug release rates and attaching antibodies at the outer shell layers for targeted drug delivery.

"We may be able to drastically increase the efficiency of existing low-soluble cancer drugs by way of their nanoparticle formulation," says Lvov. "We are working with several other institutions around the country that are currently in the process of testing our new drug formulation."

"The application of his approach to nanoassembly into clinical drug delivery will enable further improvements in cancer therapy that may reduce some of the traumatic impact of current methods," states Napper.

Pharma Focus Asia is not the first publication to recognize Lvov's pioneering work in nanoencapsulation and drug reformulation. He has had over 160 papers on the topic published in peer-reviewed journals and, last November, was named the 2007 Innovator of the Year by Small Times Magazine for his work in this area.

But Lvov is quick to point out that he is not alone in this endeavor.

"This is not singular research. Drs. Mark DeCoster, David Mills, Patrick O'Neal and many Ph.D. students at the Institute for Micromanufacturing are diligently working on different parts of our drug nanoencapsulation program."

"Dr. Lvov's accomplishments contribute greatly to Louisiana Tech's international stature in the nanotechnology field," says Dr. Leslie Guice, vice president for research and development at Louisiana Tech. "He is highly respected among the research community and has built strong collaborations with top-notch researchers nationally and internationally."

In addition to the medical benefits of this research, there could also be a significant economic benefit for northern Louisiana.

"Nanoencapsulation research is of significant interest to pharmaceutical companies," explains Guice. "This could play an important role in helping us attract some of these companies to Louisiana."

"We (Louisiana Tech) are not making a new drug," explains Lvov. "But just as important, we are the engineers working in nanotechnology to make new, more efficient formulations for existing drugs."

The strength and success of this program will continue to be built upon the collaboration of Louisiana Tech researchers with those of other institutions.

"We hope that the partnerships Dr. Lvov has developed with other institutions will continue to produce significant advances in medicine and in basic science," says Napper.

Lvov believes there is another important benefit of his research and the national and international publicity it is receiving.

"This exposure allows other people, domestic and abroad, to see that some of the best medical nanotechnology research programs in the country are located here at Louisiana Tech University."


'/>"/>

Contact: Dave Guerin
dguerin@latech.edu
318-257-4854
Louisiana Tech University
Source:Eurekalert

Related biology news :

1. Louisiana Tech researchers investigate tracking, sensors to assist Air Force
2. Researchers identify proteins involved in new neurodegenerative syndrome
3. Texas researchers and educators head for Antarctica
4. MGH researchers describe new way to identify, evolve novel enzymes
5. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
6. U of MN researchers discover noninvasive diagnostic tool for brain diseases
7. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
8. Researchers discover new strategies for antibiotic resistance
9. Researchers find new taste in fruit flies: carbonated water
10. Binghamton University researchers investigate evolving malaria resistance
11. UIC researchers find promising new targets for antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: